These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 12848110)

  • 1. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison.
    Gottlieb AB; Chaudhari U; Baker DG; Perate M; Dooley LT
    J Drugs Dermatol; 2003 Jun; 2(3):260-6. PubMed ID: 12848110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis.
    Chandran V; Gottlieb A; Cook RJ; Duffin KC; Garg A; Helliwell P; Kavanaugh A; Krueger GG; Langley RG; Lynde C; McHugh N; Mease P; Olivieri I; Rahman P; Rosen CF; Salvarani C; Thaci D; Toloza SM; Wong MY; Zhou QM; Gladman DD
    Arthritis Rheum; 2009 Sep; 61(9):1235-42. PubMed ID: 19714610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
    Langley RG; Ellis CN
    J Am Acad Dermatol; 2004 Oct; 51(4):563-9. PubMed ID: 15389191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.
    Berth-Jones J; Grotzinger K; Rainville C; Pham B; Huang J; Daly S; Herdman M; Firth P; Hotchkiss K
    Br J Dermatol; 2006 Oct; 155(4):707-13. PubMed ID: 16965419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index.
    Berth-Jones J; Thompson J; Papp K;
    Br J Dermatol; 2008 Aug; 159(2):407-12. PubMed ID: 18565187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.
    Chow C; Simpson MJ; Luger TA; Chubb H; Ellis CN
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1406-14. PubMed ID: 25917315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
    Papp K; Bissonnette R; Krueger JG; Carey W; Gratton D; Gulliver WP; Lui H; Lynde CW; Magee A; Minier D; Ouellet JP; Patel P; Shapiro J; Shear NH; Kramer S; Walicke P; Bauer R; Dedrick RL; Kim SS; White M; Garovoy MR
    J Am Acad Dermatol; 2001 Nov; 45(5):665-74. PubMed ID: 11606914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
    Gottlieb AB; Evans R; Li S; Dooley LT; Guzzo CA; Baker D; Bala M; Marano CW; Menter A
    J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XP-828L in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study.
    Poulin Y; Bissonnette R; Juneau C; Cantin K; Drouin R; Poubelle PE
    Altern Med Rev; 2007 Dec; 12(4):352-9. PubMed ID: 18069904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of etanercept as monotherapy for psoriasis.
    Gottlieb AB; Matheson RT; Lowe N; Krueger GG; Kang S; Goffe BS; Gaspari AA; Ling M; Weinstein GD; Nayak A; Gordon KB; Zitnik R
    Arch Dermatol; 2003 Dec; 139(12):1627-32; discussion 1632. PubMed ID: 14676082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician's Global Assessment.
    Simpson MJ; Chow C; Morgenstern H; Luger TA; Ellis CN
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1415-20. PubMed ID: 25917214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.
    Skov L; Kragballe K; Zachariae C; Obitz ER; Holm EA; Jemec GB; Sølvsten H; Ibsen HH; Knudsen L; Jensen P; Petersen JH; Menné T; Baadsgaard O
    Arch Dermatol; 2003 Nov; 139(11):1433-9. PubMed ID: 14623703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
    Jacobson CC; Kimball AB
    Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
    Carlin CS; Feldman SR; Krueger JG; Menter A; Krueger GG
    J Am Acad Dermatol; 2004 Jun; 50(6):859-66. PubMed ID: 15153885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.